Evidence map›Paper›PMID 41410846›Full record

ReviewCurrent atherosclerosis reports2025

Semaglutide and Tirzepatide for the Treatment of Obesity and Weight-Related Comorbidities: A Narrative Review.

Zeb Ijaz Saeed, Caroline M Apovian

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current atherosclerosis reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Zeb Ijaz SaeedCenter for Weight Management and Wellness, Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Boston, MA, USA. zisaeed@bwh.harvard.edu.ORCID http://orcid.org/0000-0002-8195-5890
Caroline M ApovianCenter for Weight Management and Wellness, Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0002-8029-1922

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThis review provides practitioners with an up-to-date overview of the efficacy and safety data of the currently approved weekly Nutrient-Stimulated Hormone (NuSH) therapies, semaglutide and tirzepatide, in managing obesity and weight-related comorbidities. RECENT

findingsIn people with overweight/obesity without diabetes, semaglutide achieved 10.8–14.8% and tirzepatide 17.4–20.8% greater weight loss than placebo. These agents’ pleotropic effects have translated into clinicals trials showing improvement in cardiovascular outcomes, improved quality of life and/or heart failure events in heart failure with preserved ejection fraction, resolution of steatohepatitis and improvement in liver fibrosis, prevention and treatment of type 2 diabetes, and improvement in renal function in chronic kidney disease. Semaglutide has additionally been shown to improve osteoarthritis symptoms and tirzepatide reduces obstructive sleep apnea severity.

Indexed as

Anti-Obesity AgentsGlucagon-Like PeptidesObesityComorbidityDiabetes Mellitus, Type 2HumansSemaglutideTirzepatideWeight LossAnti-Obesity AgentsGlucagon-Like PeptidesSemaglutideTirzepatideCardiometabolic outcomesNutrient-Stimulated hormone (NuSH) therapiesSafety and efficacySemaglutideTirzepatideWeight-Related comorbidities

Identifiers

PMID41410846

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.